Abstract
A phase II trial of cytarabine, cisplatin, and etoposide was conducted in 38 patients with refractory stage III and IV non-Hodgkin's lymphoma. There were two complete and nine partial responses (32%) among 35 evaluable patients. Response rate in patients with large cell lymphoma was 45%. The dose-limiting toxic effect was myelosuppression in 66% of patients.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cisplatin / administration & dosage
-
Cytarabine / administration & dosage
-
Drug Evaluation
-
Etoposide / administration & dosage
-
Female
-
Hematologic Diseases / chemically induced
-
Humans
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / pathology
-
Male
Substances
-
Cytarabine
-
Etoposide
-
Cisplatin